Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
14
CIMA_AEMPS:11
EMA:3
Clinical Trials
No trials found
News
Shield Therapeutics' ACCRUFeR Receives FDA Priority Review for Pediatric Iron Deficiency Anemia
The FDA has granted Priority Review status to Shield Therapeutics' ACCRUFeR (ferric maltol) for treating iron deficiency anemia in adolescents aged 10 years and above, with approval anticipated in 2026.